📰 Per Plotnikof News
Page 3 - Per Plotnikof News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Per Plotnikof. Real-time updates on events, politics, business and more.
August 18, 2023
On Thursday, 24 August 2023 ALK releases its six-month interim report 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm at which Management will review the...
June 8, 2023
Primary and all key secondary confirmatory endpoints were met, with an improvement in the total combined allergic rhinitis score of 22% compared to placebo . Results were highly statistically... | June 8, 2023
May 9, 2023
Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in...
April 17, 2023
ALK’s overall results in Q1 2023 were largely as expected with 7% organic revenue growth in local currencies and increasing operating profit . Combined SCIT and SLIT-drops sales exceeded... | April 17, 2023
February 10, 2023
10.02.2023 - ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that Claus Steensen Sølje will take up the position as Executive Vice President, Chief Financial Officer (CFO) and member of the Board of Management no later than 1 June 2023. He succeeds Søren ...
January 25, 2023
/PRNewswire/ -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and...
December 21, 2022
         ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Henriette Mersebach will take up the position as Executive Vice President,...
August 4, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
July 3, 2022
Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI CongressThe...
June 27, 2022
27.06.2022 - ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy. The trial marks the formal start of clinical ...